Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort
Thyroid2015Vol. 25(4), pp. 386–391
Citations Over TimeTop 10% of 2015 papers
C. Chougnet, Isabelle Borget, Sophie Leboulleux, Christelle de la Fouchardière, F. Bonichon, Lise Crinière, Patricia Niccoli, Stéphane Bardet, Olivier Schneegans, Sylvie Zanetta, Claire Schvartz, D. Drui, Bruno Chauffert, V. Rohmer, Martin Schlumberger
Abstract
Vandetanib is an effective option for patients with advanced MTC. AEs should be monitored carefully and should be minimized by educating both patients and care providers and by applying symptomatic treatment and dose reduction.
Related Papers
- → Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid Cancer(2022)30 cited
- → Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect(2023)28 cited
- → Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report(2018)10 cited
- → Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer(2012)1 cited
- Experience with vandeta nib in medullary thyroid cancer(2014)